About Michael West, Ph.D.Prior to founding AgeX Therapeutics (NYSE US: AGE) in 2017 to develop therapeutics related to human aging, Michael D. West, Ph.D. was CEO/Co-CEO of BioTime Inc., a leader in the regenerative medicine space, for ten years. Prior to that, he was Chairman and CEO of Advanced Cell Technology, which, as Ocata Therapeutics, was acquired by Astellas Pharma of Japan in 2016 for $379 Million. In 1990 Dr. West founded Geron Corp., where he created the research consortium that led to the first isolation of human embryonic stem cells. Dr. West is the author of numerous papers in peer-reviewed scientific journals as well as The Immortal Cell: One Scientist’s Quest to Solve the Mystery of Aging (Doubleday, 2003). He received a B.S. from Rensselaer Polytechnic Institute, an M.S. in Biology from Andrews University, and a Ph.D. from Baylor College of Medicine. He has been interviewed on NBC’s “Meet the Press” and has testified before the U.S. Congress on the potential benefits of regenerative medicine.
May 10, 2021
A team of researchers, including Michael West of AgeX Therapeutics, has authored a review paper that posits a fundamental difference between "immortal" germline cells and "mortal" somatic cells. The two types of cells This review paper, which cites 175 other papers, goes back throughout history, discussing the very earliest scientific theories of aging. It talks...